

DETAILED ACTION

Status of Claims

1. Claims 14-20 are rejected. Claims 21-25 are withdrawn.
2. Claims 14, 20-22, 24 and 25 are pending in this application. Claims 15-19 and 23 have been cancelled. This action is in response to the applicants' amendment after a final action and reply filed on December 18, 2007.

Status of Rejections

3. Claims 14 and 20 are rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting an essential element, such omission amounting to a gap between the elements. The rejection of Claims 14 and 20 are hereby withdrawn in view of applicants' amendments to claims 14 and 20.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior office action.

Examiner's Amendment

4. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Charles A. Muserian on January 15, 2008.

The amendments to the claims are as follows:

- a) Claim 14 is amended at the end of the claim to read, "...or a pharmaceutically acceptable salt thereof." from "...and its pharmaceutically acceptable salts."
- b) Claim 20 is amended at the end of the claim to read, "...or a pharmaceutically acceptable salt thereof." from "...and the pharmaceutically acceptable salts of the latter."
- c) Claims 21, 22, 24, and 25 are cancelled.

Examiner's Reasons for Allowance

5. The following is an examiner's statement of reasons for allowance:

Lassauniere, et. al. (U.S. Patent No. 6,335,445) teaches compounds and compositions that are similar in scope to the compounds and compositions in the current application. However they fail to teach the exact compounds and compositions with the specific residue groups attached in the appropriate positions. The current application has the added feature of restricting A to a substituted aniline group and B to a thienyl group.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee, and to avoid delays, should preferably accompany the issue fee. Such submissions should clearly be labeled "Comments on the Statements of Reasons for Allowance".

Conclusion

6. Claims 14 and 20 are allowed.

Art Unit: 1624

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey H. Murray whose telephone number is 571-272-9023. The examiner can normally be reached on Mon.-Thurs. 7:30-6pm EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached at 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Jeffrey H Murray/
Examiner, Art Unit 1624

**/James O. Wilson/
Supervisory Patent Examiner
Art Unit 1624**